Lung Cancer Staging: A New Focus on Lymph Node Assessment
Recent research presented at the 2026 Society of Thoracic Surgeons (STS) Annual Meeting is prompting a re-evaluation of how surgeons assess the spread of non–small cell lung cancer (NSCLC). The findings highlight the critical need for expanded lymph node evaluation during surgery to improve staging accuracy and, patient outcomes.
The Challenge of Accurate Staging
Currently, surgical standards vary regarding the number of lymph nodes examined for metastasis in patients whose imaging suggests no spread of cancer (clinically node-negative NSCLC). In North America, guidelines recommend assessing three N2 nodes and one N1 node. Still, new data suggests this may not be sufficient.
Researchers analyzing data from the STS General Thoracic Surgery Database (GTSD)—a database containing nearly 800,000 procedure records—discovered that more cancers were identified in N1 nodes than N2 nodes. These N1 nodes are located adjacent to the bronchi, making thorough evaluation particularly vital.
Why Expanded Node Dissection Matters
“We are narrowing down the best techniques for lymph node dissections in patients with lung cancer to give the best chance of identifying any cancer that is there and improving survival,” explained Dr. Christopher Seder, a thoracic surgeon at Rush University Medical Center, Chicago.
The study reviewed 48,779 patients with clinically node-negative NSCLC, finding that 11.2% were upstaged following surgery. This means that cancer spread was identified during surgery that wasn’t apparent on initial imaging. Expanded lymph node dissection could lead to earlier identification of spread and prompt the apply of appropriate systemic treatments.
The GTSD data underscores the value of large-scale, real-world data analysis in shaping clinical practice. The database captures detailed information on patient characteristics, surgical procedures, and outcomes, providing a national benchmark for quality improvement.
The Role of Pathologists
The need for accurate staging isn’t solely on surgeons. Dr. Seder emphasized the importance of pathologists conducting a thorough evaluation of lung specimens to identify all potentially cancerous lymph nodes. This collaborative approach is crucial for ensuring accurate diagnoses and treatment plans.
Future Trends in Lymph Node Assessment
These findings are likely to influence future updates to lymph node dissection guidelines. Surgeons are facing increasingly complex decisions about which lymph nodes to remove, and this research provides valuable insights to guide those choices.
The emphasis on N1 nodes represents a shift in focus. More comprehensive dissection and meticulous pathological examination will likely grow standard practice, leading to more accurate staging and personalized treatment strategies.
Frequently Asked Questions
- What are lymph nodes?
- Lymph nodes are small, bean-shaped structures that are part of the immune system. They can trap cancer cells that have spread from the primary tumor.
- What is NSCLC?
- NSCLC stands for non-small cell lung cancer, the most common type of lung cancer.
- Why is lymph node staging important?
- Accurate lymph node staging helps determine the extent of cancer spread and guides treatment decisions.
- What is the GTSD?
- The GTSD is the STS General Thoracic Surgery Database, a large clinical database used for research and quality improvement.
Learn More: Explore the STS National Database for more information on the GTSD and its impact on surgical care.
Was this article helpful? Share your thoughts in the comments below, and explore other articles on lung cancer treatment and prevention.
